B[AI pharmaceutical concept rebounded with shock and Bepsis rose more than 10%] On October 28, the AI pharmaceutical concept rebounded in shock in early trading, with Bepsis rising by more than 10%, and Northrop Grumpy, Yiqiao Shenzhou, Hualan, Medicilon, Hengrui Pharmaceuticals, and Hongbo Pharmaceuticals all rose by more than 5%. On the news, on October 28, Anthropic announced that its life sciences team has established in-depth research cooperation with six new drug research and development institutions, including Bristol-Myers Squibb and Generate Biomedicines, and has launched independent drug discovery projects. The first direction is rare childhood muscular dystrophy, with Claude responsible for most of the scientific and operational work. B[The concept of innovative drugs continues to weaken, and InnoCare falls more than 10%] On September 24th, the concept of innovative drugs continued to weaken. InnoCare once shot up and turned red in the afternoon and then quickly fell back. It is now down more than 10%. Previously, Harbin Pharmaceutical Co., Ltd. fell by the limit, and Chengda Pharmaceutical, Medicilon, Bepsis, Ellis, Enos, Kelun Pharmaceutical and other stocks fell more than 6%. B[AI pharmaceutical concept rebounded with shock and Chengdu Pioneer rose by more than 10%] On September 16th, the AI pharmaceutical concept rebounded with shock and rebound in the afternoon, with Chengdu Pioneer rising by more than 10%. Nearshore Protein, Kailer Shares, Medicilon, Hongbo Pharmaceutical, Boji Pharmaceutical, and Yaoshi Technology were among the top gainers. In terms of news, on September 14, the State Council Information Office held a press conference to introduce the decisive progress in promoting the construction of a healthy China. The National Health Commission proposed that attention should be paid to technological empowerment, especially the widespread application of artificial intelligence technology and biotechnology in the health field.
— All loaded —
